Login to Your Account

Unlikely Alliance: Rivals TKT, Genzyme Team Up Over I2S

By Kim Coghill

Friday, October 10, 2003
In a conference call earlier this year, Michael Astrue, president and CEO of Transkaryotic Therapies Inc., said he would consider signing a partner to help market and develop a potential enzyme replacement therapy for a rare genetic disorder called Hunter syndrome. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription